Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Rheumatology International

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00296-014-3125-9PMID 25208527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

  2012cited by this paper
• Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age

  2012cited by this paper
• Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.

  2011cited by this paper
• American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis

  2011cited by this paper
• Report on malignancies in the German juvenile idiopathic arthritis registry.

  2011cited by this paper
• Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.

  2009cited by this paper
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• Clinical Remission in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Anti-Tumor Necrosis Factor Agents

  2009cited by this paper
• Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years

  2008influential reference
• Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  2008cited by this paper
• Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

  2008cited by this paper
• Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.

  2006cited by this paper
• Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.

  2006cited by this paper
• Etanercept and uveitis in patients with juvenile idiopathic arthritis.

  2005cited by this paper
• The German etanercept registry for treatment of juvenile idiopathic arthritis

  2004cited by this paper
• Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.

  2003cited by this paper
• Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.

  2003cited by this paper
• A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

  2000cited by this paper
• Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

  2000cited by this paper
• Statistics with confidence

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis.

  1995cited by this paper
• Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis.

  1992cited by this paper
• Textbook of pediatric rheumatology

  1982cited by this paper
• Ef fi cacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

  year unknowncited by this paper

• Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.

  2024cites this paper
• Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

  2021cites this paper
• OBSIDIAn - real world evidence of Originator to BioSImilar Drug switch in juvenile idiopathic arthritis.

  2021cites this paper
• Hypersensitivity Reactions to Monoclonal Antibodies in Children

  2020cites this paper
• Efficacité et tolérance des agents biologiques dans les rhumatismes inflammatoires à début juvénile dans les essais cliniques randomisés et les études observationnelles

  2019cites this paper
• Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method

  2019cites this paper
• The many shades of enhancement: timing of post-gadolinium images strongly influences the scoring of juvenile idiopathic arthritis wrist involvement on MRI

  2016cites this paper
• Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis

  2016cites this paper